Fierce Pharma
October 14th 2022
”Despite pandemic slowdown, biosimilars keep gaining market share in the US.
In terms of approval and launches, the biosimilars industry experienced a slowdown during the pandemic.
But in the lab, there has been no such stagnation in the development of copycats.
A global snapshot from March of each year of the last four years shows 77 programs in 2019 followed by 79(2020) 90(2021) and 96(2022)
The most potentially impactful biosimilars are coming to the US market in 2023.”
This bodes well for PIQ’s Analytical Services.
Relationship with Sonic looks strong, page-7
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.090(9.18%) |
Mkt cap ! $140.1M | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | $1.07 | 98.0¢ | $279.6K | 277.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 967 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 4899 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |